Status:
COMPLETED
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Lead Sponsor:
Sadat City University
Collaborating Sponsors:
Beni-Suef University
Conditions:
Diabete Type 2
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.
Eligibility Criteria
Inclusion
- Type 2 male/female diabetic patients
- Age 20-70 years
- A1C less than 10.5%
Exclusion
- Type 1 diabetes; HbA1c \> 10.5%
- Pregnancy
- Chronic liver disease
- Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.
- High bilirubin
- Albumin \< 3.5 g/dl
- INR \>1-2 Diabetic ketoacidosis
- Urinary tract infection (UTI)
- Pancreatitis \< 6 months prior to enrolment
- Renal impairment (creatinine clearance ≤50 ml/min)
- Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment
- Non-compliance with follow-up visits.
Key Trial Info
Start Date :
September 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2022
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT05359341
Start Date
September 20 2020
End Date
January 10 2022
Last Update
May 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Sadat City
El Sadat, Egypt